LifeStance Health Group, Inc. (LFST)
LifeStance Health Group, Inc. (LFST)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 14,243 | 11,668 | 1,077 | -3,791 |
| Depreciation and amortization | 13,318 | 13,434 | 13,557 | 14,006 |
| Non-cash operating lease costs | 10,717 | 10,642 | 10,596 | 10,438 |
| Stock-based compensation | 15,201 | 16,704 | 18,297 | 21,116 |
| Deferred income taxes | NaN | 2,422 | NaN | NaN |
| Loss on debt extinguishment | NaN | 0 | NaN | NaN |
| Amortization of discount and debt issue costs | 251 | 257 | 256 | 255 |
| Gain on remeasurement of contingent consideration | NaN | 0 | 0 | 0 |
| Other, net | -129 | -590 | -687 | -396 |
| Patient accounts receivable, net | 26,953 | -25,363 | -8,411 | -10,886 |
| Prepaid expenses and other current assets | -33,779 | 36,275 | -4,769 | 10,664 |
| Accounts payable | -1,017 | -4,431 | 3,145 | -200 |
| Accrued payroll expenses | -26,362 | 29,555 | -15,414 | 29,265 |
| Operating lease liabilities | -9,955 | -12,300 | -12,331 | -11,604 |
| Other accrued expenses | 9,758 | -69 | -5,763 | 4,293 |
| Net cash provided by (used in) operating activities | 33,109 | 57,560 | 27,287 | 64,396 |
| Purchases of property and equipment | 10,767 | 10,911 | 10,291 | 7,755 |
| Acquisitions of businesses, net of cash acquired | 3,144 | 0 | NaN | NaN |
| Net cash used in investing activities | -13,911 | -10,911 | -10,291 | -7,755 |
| Proceeds from long-term debt, net of discount | NaN | 0 | NaN | NaN |
| Payments of debt issue costs | NaN | 0 | NaN | NaN |
| Payments of long-term debt | 0 | 1,812 | 1,813 | 1,812 |
| Payments of contingent consideration | NaN | 0 | 0 | 0 |
| Taxes related to net share settlement of equity awards | 23,936 | 98 | 209 | 236 |
| Repurchases of common stock | 49,107 | NaN | NaN | NaN |
| Net cash used in financing activities | -73,043 | -1,910 | -2,022 | -2,048 |
| Net decrease in cash and cash equivalents | -53,845 | 44,739 | 14,974 | 54,593 |
| Cash and cash equivalents - beginning of period | 248,642 | 203,903 | 188,929 | 134,336 |
| Cash and cash equivalents end of period | 194,797 | 248,642 | 203,903 | 188,929 |